

NRC FORM 313
(03-2013)
10 CFR 30, 32, 33,
34, 35, 36, 39, and 40

U.S. NUCLEAR REGULATORY COMMISSION

APPROVED BY OMB: NO. 3150-0120

EXPIRES: 08/31/2015



APPLICATION FOR MATERIALS LICENSE

Estimated burden per response to comply with this mandatory collection request 4.3 hours. Submittal of the application is necessary to determine that the applicant is qualified and that adequate procedures exist to protect the public health and safety. Send comments regarding burden estimate to the Information Services Branch (T-5 F53), U.S. Nuclear Regulatory Commission, Washington, DC 20555-0001, or by internet e-mail to Infocollect.Resource@nrc.gov, and to the Desk Officer, Office of Information and Regulatory Affairs, NE08-10202, (3150-0120), Office of Management and Budget, Washington, DC 20503. If a means used to conduct an information collection does not display a currently valid OMB control number, the NRC may not conduct or sponsor, and a person is not required to respond to, the information collection.

INSTRUCTIONS: SEE THE APPROPRIATE LICENSE APPLICATION GUIDE FOR DETAILED INSTRUCTIONS FOR COMPLETING APPLICATION. SEND TWO COPIES OF THE ENTIRE COMPLETED APPLICATION TO THE NRC OFFICE SPECIFIED BELOW. *AMENDMENTS/RENEWALS THAT INCREASE THE SCOPE OF THE EXISTING LICENSE TO A NEW OR HIGHER FEE CATEGORY WILL REQUIRE A FEE.

APPLICATION FOR DISTRIBUTION OF EXEMPT PRODUCTS FILE APPLICATIONS WITH:

OFFICE OF FEDERAL & STATE MATERIALS AND ENVIRONMENTAL MANAGEMENT PROGRAMS
DIVISION OF MATERIALS SAFETY AND STATE AGREEMENTS
U.S. NUCLEAR REGULATORY COMMISSION
WASHINGTON, DC 20555-0001

ALL OTHER PERSONS FILE APPLICATIONS AS FOLLOWS:

IF YOU ARE LOCATED IN:

ALABAMA, CONNECTICUT, DELAWARE, DISTRICT OF COLUMBIA, FLORIDA, GEORGIA, KENTUCKY, MAINE, MARYLAND, MASSACHUSETTS, NEW HAMPSHIRE, NEW JERSEY, NEW YORK, NORTH CAROLINA, PENNSYLVANIA, PUERTO RICO, RHODE ISLAND, SOUTH CAROLINA, TENNESSEE, VERMONT, VIRGINIA, VIRGIN ISLANDS, OR WEST VIRGINIA,

SEND APPLICATIONS TO:

LICENSING ASSISTANCE TEAM
DIVISION OF NUCLEAR MATERIALS SAFETY
U.S. NUCLEAR REGULATORY COMMISSION, REGION I
2100 RENAISSANCE BOULEVARD, SUITE 100
KING OF PRUSSIA, PA 19403-2713

IF YOU ARE LOCATED IN:

ILLINOIS, INDIANA, IOWA, MICHIGAN, MINNESOTA, MISSOURI, OHIO, OR WISCONSIN,
SEND APPLICATIONS TO:

MATERIALS LICENSING BRANCH
U.S. NUCLEAR REGULATORY COMMISSION, REGION III
2443 WARRENVILLE ROAD, SUITE 210
LISLE, IL 60532-4352

SEND APPLICATIONS TO:

NUCLEAR MATERIALS LICENSING BRANCH
U.S. NUCLEAR REGULATORY COMMISSION, REGION IV
1600 E. LAMAR BOULEVARD
ARLINGTON, TX 78011-4511



PERSONS LOCATED IN AGREEMENT STATES SEND APPLICATIONS TO THE U.S. NUCLEAR REGULATORY COMMISSION ONLY IF THEY WISH TO POSSESS AND USE LICENSED MATERIAL IN STATES SUBJECT TO U.S. NUCLEAR REGULATORY COMMISSION JURISDICTIONS.

1. THIS IS AN APPLICATION FOR (Check appropriate item)

A. NEW LICENSE

B. AMENDMENT TO LICENSE NUMBER 17-14996-01

C. RENEWAL OF LICENSE NUMBER _____

2. NAME AND MAILING ADDRESS OF APPLICANT (Include ZIP code)

National Hansen's Disease Programs,
Laboratory Research Branch at LSU-SVM
Skip Bertman Drive
Baton Rouge, Louisiana 70803

3. ADDRESS WHERE LICENSED MATERIAL WILL BE USED OR POSSESSED

National Hansen's Disease Programs,
Laboratory Research Branch at LSU-SVM
Skip Bertman Drive
Baton Rouge, Louisiana 70803

4. NAME OF PERSON TO BE CONTACTED ABOUT THIS APPLICATION

J. P. Pasqua

BUSINESS TELEPHONE NUMBER

(225) 578-9855

BUSINESS CELLULAR TELEPHONE NUMBER

BUSINESS EMAIL ADDRESS

JPasqua@hrsa.gov

SUBMIT ITEMS 5 THROUGH 11 ON 8-1/2 X 11" PAPER THE TYPE AND SCOPE OF INFORMATION TO BE PROVIDED IS DESCRIBED IN THE LICENSE APPLICATION GUIDE.

5. RADIOACTIVE MATERIAL

a. Element and mass number, b. chemical and/or physical form, and c. maximum amount which will be possessed at any one time.

6. PURPOSE(S) FOR WHICH LICENSED MATERIAL WILL BE USED

7. INDIVIDUAL(S) RESPONSIBLE FOR RADIATION SAFETY PROGRAM AND THEIR TRAINING EXPERIENCE.

8. TRAINING FOR INDIVIDUALS WORKING IN OR FREQUENTING RESTRICTED AREAS

9. FACILITIES AND EQUIPMENT

10. RADIATION SAFETY PROGRAM

11. WASTE MANAGEMENT

12. LICENSE FEES (Fees required only for new applications, with few exceptions*)
(See 10 CFR 170 and Section 170.31)

FEE CATEGORY

AMOUNT ENCLOSED \$

13. CERTIFICATION (Must be completed by applicant) THE APPLICANT UNDERSTANDS THAT ALL STATEMENTS AND REPRESENTATIONS MADE IN THIS APPLICATION ARE BINDING UPON THE APPLICANT

THE APPLICANT AND ANY OFFICIAL EXECUTING THIS CERTIFICATION ON BEHALF OF THE APPLICANT, NAMED IN ITEM 2, CERTIFY THAT THIS APPLICATION IS PREPARED IN CONFORMITY WITH TITLE 10, CODE OF FEDERAL REGULATIONS, PARTS 30, 32, 33, 34, 35, 36, 39, AND 40, AND THAT ALL INFORMATION CONTAINED HEREIN IS TRUE AND CORRECT TO THE BEST OF THEIR KNOWLEDGE AND BELIEF.

WARNING: 18 U.S.C. SECTION 1001 ACT OF JUNE 25, 1948 82 STAT. 749 MAKES IT A CRIMINAL OFFENSE TO MAKE A WILLFULLY FALSE STATEMENT OR REPRESENTATION TO ANY DEPARTMENT OR AGENCY OF THE UNITED STATES AS TO ANY MATTER WITHIN ITS JURISDICTION.

CERTIFYING OFFICER - TYPE PRINTED NAME AND TITLE

Renee Painter
Director in Temporary Charge

SIGNATURE

DATE

8/27/13

FOR NRC USE ONLY

TYPE OF FEE	FEE LOG	FEE CATEGORY	AMOUNT RECEIVED	CHECK NUMBER	COMMENTS
-------------	---------	--------------	-----------------	--------------	----------

			\$		
--	--	--	----	--	--

APPROVED BY

DATE



Department of Health and Humans Services

DHHS/HRSA /Healthcare System Bureau
Division of National Hansen's Disease Programs
Louisiana State University
School of Veterinary Medicine
Skip Beliman Drive
Baton Rouge, La. 70803

Date: August 23, 2013

Michelle Hammond
Health Physicist,
NRC.

Request for amendment to License No.:17-14996-01, Docket No.: 030-08380

Dear Ms. Hammond,
We are requesting the following amendments to our NRC material license number 17-14996-01:

- 1) From item #11 (page 2) the following names need to be removed as they have recently retired from National Hansen's Disease Program.
 - a. Edward Shannon, Ph.D
 - b. James L. Krahenbuhl, Ph.D.
 - c. Thomas P. Gillis, Ph.D.

- 2) In item # 11 (page 2) the following name needs to be added.
 - a. Ramanuj Lahiri, Ph.D.

A copy of Ramanuj Lahiri's CV highlighting his experience working with radioisotopes is attached along with completed NRC 313 form.
Please feel free to contact us if you have any questions.

Sincerely,

J. P. Pasqua.
Radiation Safety Officer
National Hansen's Disease Program
jpasqua@hrsa.gov

Richard W. Truman, Ph.D.
Acting Chief, Laboratory Research Branch
National Hansen's Disease Program
225-578-9848
rtruman@hrsa.gov

PUBLIC

- Immediate Release
 Normal Release

NON-PUBLIC

- A.3 Sensitive-Security Related
 A.7 Sensitive Internal
 Other: _____

Reviewer: Jwo Date: 08/29/13

Curriculum Vitae

Ramanuj Lahiri, Ph.D.
Microbiologist,
National Hansen's Disease Program
Voice: (225) 578-9844
Email: rlahiri@hrsa.gov

Training: Received theoretical training in radiation biology as part of Biophysics course in both Undergraduate (1992) and Master (1994) level in Department of Physiology, University of Calcutta, India. Basic radioisotope use and safety training as part of Master level (1994) Immunology & Microbiology laboratory course taught in the Department of Physiology, University of Calcutta, India. Advanced training in use of radioisotopes in biological research as part of Ph.D. level (1997) Research Methodology course in Department of Biotechnology, Jawaharlal Nehru University, New Delhi, India. Received on-the-job-training from NRC licensed user, James L. Krahenbuhl (2002). Received 1 hour radiation safety training (2006) at Center for Advances Microstructures & Devices (CAMD), Louisiana State University.

Experience: 15 years of experience in using radioisotopes ^3H (10 mCi), ^{32}P (<1mCi), ^{14}C (>10 mCi), ^{51}Cr (<1 mCi), & ^{131}I (<1 mCi) in various biological assays in the laboratory (since 1997).

Education:

Degree	Year	Institution	Subject	Grade
Ph.D.	2001	Jawaharlal Nehru University	Immunology	Awarded
M.Sc.	1995	University of Calcutta	Physiology	I
B.Sc.	1993	University of Calcutta	Physiology Major	I

Position Held:

January 2011 – Present: Microbiologist, NHDP, HSB, HRSA.

August 2008 – January 2011: Senior Postdoctoral Researcher, Department of Pathobiological Sciences, Louisiana State University, USA.

March 2004 – August 2008: Postdoctoral Researcher, Department of Pathobiological Sciences, Louisiana State University, USA.

January 2002 – March 2004: Research Associate, Department of Pathobiological Sciences, Louisiana State University, USA.

July 1998 – August 2001: Senior Research Fellow, School of Biotechnology, Jawaharlal Nehru University, India.

July 1996 – June 1998: Junior Research Fellow, School of Biotechnology, Jawaharlal Nehru University, India.

Awards:

1. Post Doctoral Fellowship (January 2002 to January 2004) from American Leprosy Mission, Greenville, USA.

2. Awarded Senior Research Fellowship, in 1998 from Council for Scientific and Industrial Research, Govt. of India to pursue research in biological sciences in any Indian University or Institute
3. Awarded Junior Research Fellowship, in 1996 from Council for Scientific and Industrial Research, Govt. of India, to pursue research in biological sciences in any Indian University or Institute.

Research Support:

Heiser Foundation Grant. 07/01/12 – 06/30/14.

Ramanuj Lahiri – Principal Investigator.

Thomas P. Gillis & Linda B. Adams – Co- Investigators.

Functional characterization of effector T cells eliciting protective immune response in mouse foot pad against *Mycobacterium leprae*.

American Leprosy Mission Grant. October 2011 – September 2014

Ramanuj Lahiri – Principal Investigator.

Thomas P. Gillis – Co-Principal Investigator.

Provision of highly viable nu/nu mouse derived *Mycobacterium leprae* as a unique leprosy research reagent.

Heiser Foundation Grant. 07/01/09 – 06/30/10.

James L. Krahenbuhl - Principal Investigator.

Ramanuj Lahiri – Co-Investigator.

Modulation of apoptosis by viable *Mycobacterium leprae* as an intracellular survival strategy.

Heiser Foundation Grant. 07/01/07 – 06/30/09.

James L. Krahenbuhl - Principal Investigator.

Ramanuj Lahiri – Co-Investigator.

Development of a mouse model for early detection of sub clinical leprosy.

Professional Memberships:

2004 – Present Member American Society of Microbiology.

1999 – Present Member Indian Immunology Society.

1994 – Present Member Physiological Society of India.

Publications:

1. Sharma R, **Lahiri R**, Scollard DM, P, Williams DL, Adams LB, Figarola J and Truman RW. The armadillo: a model for the neuropathy of leprosy and potentially other neurodegenerative diseases. *Disease Models & Mechanisms*, 2013, 6: 19-24.
2. **Lahiri R**, Randhawa B, Franken KLMC., Duthie MS, Spencer JS, Geluk A, and Krahenbuhl JL. Development of a Mouse Food Pad Model for Detection of Sub Clinical Leprosy. *Leprosy Review*, 2011, 82: 432-444.

3. **Lahiri R**, Randhawa B, Krahenbuhl JL. Infection of mouse macrophages with viable *Mycobacterium leprae* does not induce apoptosis. *Journal of Infectious Diseases*, 2010; 201:1736-1742.
4. Raman VS, O'Donnell J, Bailor HR, Goto W, **Lahiri R**, Gillis TP, Reed SG, Duthie MS. ML0276 vaccination reduces local inflammation, but not bacterial burden, during experimental *M. leprae* infection. *Infect Immun*, 2009; 77: 5623-5630.
5. Martinez AN, **Lahiri R**, Pittman TL, Scollard D, Truman R, Moraes MO, and Williams DL. Molecular Determination of *Mycobacterium leprae* Viability Using Real-Time PCR. *J Clin Microbiol*. 2009; 47: 2124-2130.
6. **Lahiri R**, and Krahenbuhl JL. The Role of Free-Living Pathogenic Amoeba in the transmission of Leprosy: A Proof of Principle. *Leprosy Review*, 2008; 79: 401-409.
7. **Lahiri R**, Sandoval FG, Krahenbuhl JL, and Shannon EJ. Activation of Complement by *Mycobacterium leprae* requires disruption of the bacilli. *Leprosy Review*, 2008; 79: 311-314.
8. Duthie MS, Reece ST, **Lahiri R**, Goto W, Raman VS, Kaplan J, Ireton GC, Bertholet S, Gillis TP, Krahenbuhl JL and Reed SG. Antigen-specific cellular and humoral responses are induced by intradermal *Mycobacterium leprae* infection of the mouse ear. *Infect Immun*, 2007; 75: 5290-5297.
9. Mohanty BP, **Lahiri R**, Misra-Bhattacharya S, and Kar SK. *Brugia malayi* adult low molecular weight IgG4-reactive antigens induce differential cytokine response in lymphocytes of endemic normal and asymptomatic microfilariae carriers *in vitro*. *Journal of Clinical Immunology*, 2007; 27: 397-408
10. Manjunatha UH, **Lahiri R**, Randhawa B, Dowd CS, Krahenbuhl JL, and Barry CE III. *Mycobacterium leprae* is naturally resistant to PA-824. *Antimicrobial Agents and Chemotherapy*, 2006; 50: 3350-3354.
11. **Lahiri R**, Randhawa B, Krahenbuhl JL. Effects of purification and fluorescent staining on viability of *Mycobacterium leprae*. *International Journal of Leprosy and Other Mycobacterial Diseases*, 2005; 73: 194-203.
12. **Lahiri R**, Randhawa B, Krahenbuhl JL. Application of a viability staining method for *Mycobacterium leprae* derived from the athymic (nu/nu) mouse foot pad. *Journal of Medical Microbiology*, 2005; 54: 235-242.

Oral presentations:

1. Host response to *M. leprae* infection. 2010, Invited lecture, School of Biotechnology, Jawaharlal Nehru University, New Delhi, India.
2. Early influx of CD4+ cells in the foot pads of vaccinated mice following challenge with live *Mycobacterium leprae* as a surrogate marker of protection. 2009, 44th Meeting of U.S.-Japan Joint Cooperative Medical Sciences Program in Tuberculosis and Leprosy, Fukuoka, Japan.
3. Immunological response in foot pads and lymph nodes of vaccinated mice following challenge with live *Mycobacterium leprae*. 2008, 43rd Meeting of U.S.-Japan Joint Cooperative Medical Sciences Program in Tuberculosis and Leprosy, Baltimore, USA.
4. *Mycobacterium leprae*: The well behaved pathogen. 2007, Invited lecture, School of Biotechnology, Jawaharlal Nehru University, New Delhi, India.
5. Further definition of viability of *Mycobacterium leprae* as a research resource. 2003, 38th Meeting of U.S.-Japan Joint Cooperative Medical Sciences Program in Tuberculosis and Leprosy, Newark, USA.

6. *Mycobacterium leprae* and Programmed cell death. Annual General Meeting of the South Central Branch of American Society for Microbiology. 2006, Lafayette, USA.
7. Dissecting host–parasite interaction in lymphatic filariasis. 2001, International Conference on New Horizons of Biotechnology, Trivandrum, India.

Peer-Reviewed Conference Papers:

1. **R. Lahiri**, and J. L. Krahenbuhl. Free-living pathogenic amoebae as potential reservoirs / vectors in leprosy transmission. 2008, 17th International Congress, Hyderabad, India.
2. **R. Lahiri**, and J. L. Krahenbuhl. Provision of fresh, viable *Mycobacterium leprae* as a research reagent. 2008, 17th International Congress, Hyderabad, India.
3. **R. Lahiri**, B. Randhawa and J. L. Krahenbuhl. Viable *Mycobacterium leprae* does not Induce Apoptosis in Infected Murine Macrophages. 2008, 17th International Congress, Hyderabad, India.
4. **R. Lahiri**, F. Sandoval, J. L. Krahenbuhl, and E. J. Shannon. Activation of complement by *Mycobacterium leprae* requires disruption of the bacilli. 2008, 17th International Congress, Hyderabad, India.
5. **R. Lahiri**, B. Randhawa and J. L. Krahenbuhl. Contrasting apoptotic effects of *Mycobacterium leprae* and *Mycobacterium tuberculosis* on infected murine macrophages. 2005, 40th Meeting of U.S.-Japan Joint Cooperative Medical Sciences Program in Tuberculosis and Leprosy. Seattle, USA.
6. **R. Lahiri**, B. Randhawa and J. L. Krahenbuhl. *Mycobacterium leprae* does not induce apoptosis *in vitro* in mouse peritoneal macrophages. 2005, 105th Annual General Meeting of American Society for Microbiology. New Orleans, USA.
7. **R. Lahiri**, B. Randhawa and J. L. Krahenbuhl. A rapid and reliable method to measure viability in *Mycobacterium leprae*. 2003, 103rd Annual General Meeting of American Society for Microbiology. Washington D.C., USA.
8. **R. Lahiri**, B. Randhawa and J. L. Krahenbuhl. Viable *Mycobacterium leprae* as a research resource: evaluation of fluorescent staining for live and dead *Mycobacterium leprae*. 2002, 16th International Leprosy Congress. Salvador, Brazil.
9. B.P. Mohanty, **R. Lahiri**, S. Bhattacharya, and S. K. Kar. *Brugia malayi* adult <24kd antigens preferentially induce Th1 cytokine response in endemic normal individuals. 2001, Abstract A6. *Scandinavian J. Immunol.* **54** (Suppl.1): 88



August 21st; 2013

To Whom It May Concern:

This letter certifies that Dr. Ramanuj Lahiri has successfully been re-certified in radiation safety each year since he became a CAMD user in 2007. In addition, he completed a rigorous written test that generally requires multiple attempts to achieve a passing grade. Since becoming a member of the CAMD Synchrotron Ring user community, Dr. Lahiri has always completed his radiation safety training in a diligent and timely matter.

Should you have any additional questions that I may answer, please feel free to contact me.

Sincerely,

Marie-Lorraine Mpresau-Day

Lorraine Day, PhD

CAMD RSO

6980 Jefferson Hwy

Baton Rouge, LA 70806

225-578-4616

Murnahan, Colleen

From: Hammond, Michelle
Sent: Monday, August 26, 2013 10:57 AM
To: Hill, Carol
Cc: Murnahan, Colleen
Subject: FW: Amendment Request Form
Attachments: image001.png; Amendment Request for 17-14996-01.pdf

Hi Carol and Colleen,

A licensee sent me an amendment request. Can one of you please set up the action.??

Thanks.
Michelle Hammond

From: Lahiri, Ramanuj (HRSA) [RLahiri@hrsa.gov]
Sent: Friday, August 23, 2013 10:24 AM
To: Hammond, Michelle
Cc: Pasqua, Joseph (HRSA)
Subject: RE: Amendment Request Form

Ms. Hammond,

Please find attached a request for an amendment to our NRC license # 17-14996-01. We are requesting removal of three user names and adding one.

Please do not hesitate to contact me or our RSO J. P. Pasqua (cc-d in this mail) if you need anything else.

Thanks,

Ramanuj

Ramanuj Lahiri, Ph.D.
National Hansen's Disease Program,
Baton Rouge, LA 70803.
Ph: (225) 578-9844
Fax: (225) 578-9856.

From: Hammond, Michelle [Michelle.Hammond@nrc.gov]
Sent: Tuesday, July 16, 2013 2:19 PM
To: Lahiri, Ramanuj (HRSA)
Subject: Re: Amendment Request Form

Dr. Lahiri,

As discussed, please find the link below for amendment request form 313.

<http://www.nrc.gov/reading-rm/doc-collections/forms/nrc313.pdf>

You can scan everything into a .pdf document and e-mail the request and additional information in, if you prefer.

Please don't hesitate to contact me if you have any questions.

Thanks.

Best Regards,

Michelle M. Hammond, M.Sc.
Health Physicist
Region IV-Division of Nuclear Materials Safety, Branch B
office) 817-200-1127
fax) 817-200-1188
[NRC]

BETWEEN:

Accounts Receivable/Payable
and
Regional Licensing Branches

[FOR ARPB USE]
INFORMATION FROM WBL

Program Code: 03620
Status Code: Pending Amendment
Fee Category: 3M
Exp. Date: 02/29/2012
Fee Comments: 170.11(A)(5)
Decom Fin Assur Req: N

License Fee Worksheet - License Fee Transmittal

A. REGION

1. APPLICATION ATTACHED

Applicant/Licensee: HEALTH & HUMAN SERVICES, DEPT. OF
Received Date: 08/26/2013
Docket Number: 3008380
Mail Control Number: 581625
License Number: 17-14996-01
Action Type: Amendment

2. FEE ATTACHED

Amount: _____

Check No.: _____

3. COMMENTS

Signed: Colleen Murnahan
Date: 8/26/13

B. LICENSE FEE MANAGEMENT BRANCH (Check when milestone 03 is entered / /)

1. Fee Category and Amount: _____

2. Correct Fee Paid. Application may be processed for:

Amendment: _____

Renewal: _____

License: _____

3. OTHER _____

Signed: _____

Date: _____



DATE
08/22/2013

NAME AND ADDRESS OF APPLICANT AND/OR LICENSEE

Department of Health & Human Services
National Hansen's Disease Program
USPHS, Laboratory Research Branch at LSU-SVM
Skip Bertman Drive
Baton Rouge, LA 70803 ATTN: Renee Painter

LICENSE NUMBER

17-14996-01

MAIL CONTROL NUMBER

581625

LICENSING AND/OR TECHNICAL REVIEWER

cmurnahan

This is to acknowledge the receipt of your:

LETTER and/or APPLICATION DATED: 08/22/2013

The initial processing, which included an administrative review, has been performed.

AMENDMENT TERMINATION NEW LICENSE RENEWAL

- There were no administrative omissions identified during our initial review.
- This is to acknowledge receipt of your application for renewal of the material(s) license identified above. Your application is deemed timely filed, and accordingly, the license will not expire until final action has been taken by this office.
- Your application for a new NRC license did not include your taxpayer identification number. Please fill out NRC Form 531, located at the following link:

<http://www.nrc.gov/reading-rm/doc-collections/forms/nrc531.pdf>

Send the completed NRC Form 531, by facsimile, to the following number: (301) 415-5387

A copy of your action has been emailed to our License Fee and Accounts Receivable Branch, in our Headquarters office in Rockville, MD. You will be contacted separately if there is a fee issue involved.

Your application has been assigned the above listed **MAIL CONTROL NUMBER**. When calling to inquire about this action, please refer to this control number. Your application has been forwarded to a technical reviewer. Please note that the technical review, which is normally completed within 180 days for a renewal application (90 days for all other requests), may identify additional omissions or require additional information. If you have any questions concerning the processing of your application, our contact information is listed below:

Region IV
U. S. Nuclear Regulatory Commission
DNMS/NMSB - B
1600 E. Lamar Blvd.
Arlington, TX 76011-4511
(817) 200-1103 or (817) 200-1140

emailed to licensee